Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 13Other hematologic neoplasm 7Thoracic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2CNS 2Breast 2Sarcoma 1Plasma cell 1Head & Neck 1

Conditions

Colorectal Neoplasms 16Stomach Neoplasms 7Melanoma 7Rectal Neoplasms 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Colonic Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Renal Cell 3Carcinoma, Merkel Cell 3Anus Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Prostatic Neoplasms 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2

Interventions

pembrolizumab 6Nivolumab 5Magnetic Resonance Spectroscopy 4fludarabine 3Sirolimus 3Radiotherapy 3Methods 3Gemcitabine 3Early Intervention, Educational 3Drug Therapy 3Biopsy 3spartalizumab 2epacadostat 2atezolizumab 2X-Rays 2Topotecan 2Surveys and Questionnaires 2Specimen Handling 2Palliative Care 2Nuclear Medicine Department, Hospital 2Ipilimumab 2Interleukin-2 2Educational Status 2Dasatinib 2Cyclophosphamide 2Carboplatin 2vocimagene amiretrorepvec 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × Interleukin-2 × Gastrointestinal × Clear all
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡